Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Hernandez-Camba, A.
  • Arranz, L.
  • Vera, I
  • Carpio, D.
  • Calafat, M.
  • Lucendo, A. J.
  • Taxonera, C.
  • Marin, S.
  • Garcia, M. J.
  • Marin, G. Suris
  • Rodriguez, E. Sanchez
  • Carbajo, A. Y.
  • De Castro, M. L.
  • Martin-Cardona, A.
  • Rodriguez-Lago, I
  • Busquets, D.
  • Bertoletti, F.
  • Ausin, M. Sierra
  • Tardillo, C.
  • Malaves, J. Huguet
  • Bujanda, L.
  • Castaño A
  • Domènech E
  • Ramos, L.
  • GETECCU (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa)

Grupos

Abstract

BACKGROUND: Studies to evaluate the use of mycophenolate mofetil (MMF) in inflammatory bowel disease (IBD) are limited after the appearance of biological treatments. AIMS: Our primary objective was to evaluate the effectiveness and safety of MMF in IBD. METHODS: IBD patients who had received MMF were retrieved from the ENEIDA registry. Clinical activity as per the Harvey-Bradshaw Index (HBI), partial Mayo score (pMS), physician global assessment (PGA) and C-reactive protein (CRP) were reviewed at baseline, at 3 and 6 months, and at final follow-up. Adverse events and causes of treatment discontinuation were documented. RESULTS: A total of 83 patients were included (66 Crohn's disease, 17 ulcerative colitis), 90% of whom had previously received other immunosuppressants. In 61% of patients systemic steroids were used at initiation of MMF, and in 27.3% biological agents were co-administered with MMF. Overall clinical effectiveness was observed in 64.7% of the population. At the end of treatment, 45.6% and 19.1% of subjects showed remission and clinical response, respectively. MMF treatment was maintained for a median of 28.9 months (IQR: 20.4-37.5). CONCLUSION: Our study suggests, in the largest cohort to date, that MMF may be an effective alternative to thiopurines and methotrexate in IBD.

Copyright © 2021 Elsevier Ltd. All rights reserved.

Datos de la publicación

ISSN/ISSNe:
1590-8658, 1878-3562

DIGESTIVE AND LIVER DISEASE  ELSEVIER SCIENCE INC

Tipo:
Article
Páginas:
635-641
PubMed:
34862115
Factor de Impacto:
0,979 SCImago
Cuartil:
Q2 SCImago

Citas Recibidas en Web of Science: 4

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Crohn's disease; Inflammatory bowel disease; Mycophenolate mofetil; Ulcerative colitis

Campos de Estudio

Compartir